Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,591,039 shares, an increase of 6.7% from the August 15th total of 3,365,104 shares. Based on an average daily volume of 117,847 shares, the days-to-cover ratio is presently 30.5 days. Approximately 10.9% of the shares of the company are short sold.
A number of hedge funds have recently modified their holdings of AST. LMR Partners LLP purchased a new stake in Asterias Biotherapeutics during the 2nd quarter valued at about $110,000. Millennium Management LLC purchased a new stake in Asterias Biotherapeutics during the 4th quarter valued at about $132,000. Renaissance Technologies LLC purchased a new stake in Asterias Biotherapeutics during the 2nd quarter valued at about $142,000. Deutsche Bank AG boosted its holdings in Asterias Biotherapeutics by 110.5% during the 4th quarter. Deutsche Bank AG now owns 66,180 shares of the biotechnology company’s stock valued at $148,000 after acquiring an additional 34,739 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in Asterias Biotherapeutics during the 2nd quarter valued at about $194,000.
Several research firms recently commented on AST. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Asterias Biotherapeutics in a research report on Tuesday, June 19th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Tuesday, July 10th. Raymond James cut Asterias Biotherapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, August 10th. Finally, B. Riley set a $6.00 price objective on Asterias Biotherapeutics and gave the stock a “buy” rating in a report on Friday, August 3rd.
Shares of AST traded up $0.08 during midday trading on Friday, reaching $1.23. The stock had a trading volume of 73,962 shares, compared to its average volume of 201,483. Asterias Biotherapeutics has a 12-month low of $1.07 and a 12-month high of $3.45.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.11 million.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Recommended Story: What is a stock split?
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.